Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

FinalSpark Launches the First Remote Research Platform Using Human Neurons for Biocomputing


FinalSpark, a pioneering Swiss biocomputing startup, has launched the first-ever online platform enabling global researchers to conduct experiments remotely on biological neurons in vitro. The platform provides around-the-clock access to 16 human brain organoids aimed at developing the world's first living processor. These bioprocessors, composed of living neurons capable of learning and processing information, consume a million times less power than traditional digital processors, potentially reducing the environmental impact associated with the rising use of computers.

Already, three dozen universities have expressed interest in using the platform. In a testament to our commitment to collaboration, FinalSpark has granted free access to nine institutions for Research Use Only. As the demand for our neuroplatform grows, we are prepared to scale up to meet it, all with the shared goal of building the world's first living processor. "We firmly believe that such an ambitious goal can only be achieved through international collaboration," asserts Dr. Fred Jordan, co-founder of FinalSpark.

Additional details about the Neuroplatform and the application process for research institutions are available on FinalSpark's website at https://finalspark.com/neuroplatform. A scientific publication detailing FinalSpark's Neuroplatform, titled "Open and remotely accessible Neuroplatform for research in wetware computing," is also available in the journal Frontiers.

The convergence of AI, recent advancements in biology, and stem cell technologies have opened up new horizons in the field of synthetic biology and wetware computing. With the launch of our neuroplatform, we are at the forefront of this exciting journey. "It is an inspiring time to be a researcher," says Dr. Martin Kutter, co-founder of FinalSpark.

About FinalSpark

Founded in 2014 and based in Switzerland, FinalSpark is at the forefront of technological innovation, pioneering the development of bioprocessors ? the next generation of digital processors. These groundbreaking bioprocessors utilize human neurons instead of traditional digital processors, marking a significant leap in processing technology.

FinalSpark offers a Neuroplatform that enables companies to conduct remote research on neuronal tissues placed on MEAs, fully supporting electrophysiological experiments. The three-dimensional neuronal structures have a long lifespan, making them suitable for experiments that run for several months.

Keywords: biocomputing, organoid intelligence, wetware computing, neuron, biology, processor, cell culture, artificial intelligence, energy, CO2


These press releases may also interest you

at 12:10
Xsolla, a global video game commerce company, announces a new partnership with Curve Games, the award-winning London-based publisher of several notable independent games. The alliance will leverage Xsolla's Web Shop to support Curve Games in...

at 12:05
Mintegral, a programmatic subsidiary of leading advertising technology company Mobvista (1860.HK), has launched an advanced model for precise user acquisition (UA). The new model, Target CPE (Cost Per Engagement), helps advertisers achieve lifetime...

at 12:00
Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its...

at 12:00
Trianz, a global digital transformation technology solutions and services firm, is thrilled to announce the appointment of Priyanshu Singh as its new VP & Chief of Staff. This strategic hire comes at a pivotal moment as Trianz continues to experience...

at 12:00
Marelli, a leading global mobility technology supplier, announced that Kelei Shen is assuming the role of Executive Vice President and President China effective July 1, 2024. He will lead Marelli's ambitious growth plans for China....

at 11:56
Northwest Biotherapeutics ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024. ...



News published on and distributed by: